Nantbio, Inc.

Immunitybio, Inc.

Nantcell, Inc.

Clifford Anders Olson

Kayvan R Niazi

Shiho Tanaka

Hermes J Garban

Nicholas James Witchey

Patrick Soon-Shiong

Philip T Liu

Raymond Wong

Wael Tadros

Heather McFarlane

Jon Thomas Van Lew

Wade Nichols Richardson

Wendy Higashide

Helty Adisetiyo

Mark Guido

Tan Trinh

Kayyan Niazi

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

Neoepitope vaccine delivery vehicle and methods of making the same

Described herein are methods of making recombinant cells using an in silico-generated pathway map of an endogenous pathway in a cell of interest to determine, in silico, a predicted effect of incorporating a recombinant nucleic acid into the endogenous pathway; and based on the predicted effect, incorporating the recombinant nucleic acid into the endogenous pathway in the cell of interest such that activation of the endogenous pathway regulates expression of the recombinant nucleic acid.

Prediction of computational pathway circuits

Soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and αCTLA4 antibody for preventing, reducing the occurrence of, and/or treating cancer or an autoimmune disease or disorder in a subject are provided herein. The methods provided herein include administering to a subject a pharmaceutical composition of a soluble fusion protein complex.

Fusion molecules of CTLA4 and IL-15

Antibodies, fragments thereof, and chimeric proteins comprising the same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

Anti-TIM3 monoclonal antibodies and chimeric antigen receptors

Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-γ secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.

Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells

Compositions, methods and uses of a recombinant virus and/or recombinant viral vector encoding a distinct antibody or antibody fragment generated from high-diversity nucleic acid library are presented. Preferably, the recombinant virus is genetically modified, low immunogenic virus, for example, an E2b-deleted adenovirus. The high-diversity nucleic acid library comprises or is derived from (1) a V-CDR1/2 sub-library, (2) a plurality of V-CDR3 sub-libraries, and (3) a Vsub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the V-CDR1/2 sub-library, the plurality of V-CDR3 sub-libraries, and the Vsub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

mRNA display antibody library and methods

The present disclosure relates to recombinant production reporter cells comprising a logic gate such that an expressible sequence (e.g., a reporter gene) is expressed after the occurrence of triggering event related to a stage of production or an environmental condition of a biological production system. Nucleic acids, kits, and methods for making and using the recombinant production reporter cells are also disclosed herein.

Method of detecting cellular reporting for therapy production

Compositions, methods and uses of high-diversity nucleic acid library that encodes a plurality of antibodies or antibody fragments are presented. The high-diversity nucleic acid library comprises or is derived from (1) a V-CDR1/2 sub-library, (2) a plurality of V-CDR3 sub-libraries, and (3) a Vsub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the V-CDR1/2 sub-library, the plurality of V-CDR3 sub-libraries, and the Vsub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

MRNA display antibody library and methods

Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.

Anti-CD30 monoclonal antibodies and chimeric antigen receptors

Compositions, methods, and uses of recombinant IL-8 antibody, fragment thereof or single chain variable fragment (scFv) having high affinity to IL-8 to target tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment includes a Vsegment comprising a first amino acid sequence selected from SEQ ID NO. 1-15, 31-32, and/or a Vsegment comprising a second amino acid sequence selected from SEQ ID NO. 16-30, 33-34. The recombinant IL-8 antibody or scFv fragment can be formulated as pharmaceutical compositions to administer to a patient having a tumor to reduce metastasis of the tumor, reduce immune suppression in the tumor microenvironment or reduce Th2 mediated immune response.

Method of treatment of a tumor with an IL-8 antibody

Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

Compositions, methods, and uses of recombinant recombinant IL-8 antibody, fragment thereof or single chain variable fragment (scFv) having high affinity to IL-8 to target tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment includes a Vsegment comprising a first amino acid sequence selected from SEQ ID NO. 1-15, 31-32, and/or a Vsegment comprising a second amino acid sequence selected from SEQ ID NO. 16-30, 33-34. The recombinant IL-8 antibody or scFv fragment can be formulated as pharmaceutical compositions to administer to a patient having a tumor to reduce metastasis of the tumor, reduce immune suppression in the tumor microenvironment or reduce Th2 mediated immune response.

Growing community of inventors

Culver City, CA, United States of America

Clifford Anders Olson